LPL Financial
HRTX icon

LPL Financial’s Heron Therapeutics HRTX Stock Holding History

LPL Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63K Buy
78,684
+22,795
+41% +$26.4K ﹤0.01% 5750
2025
Q4 		$72.7K Buy
55,889
+5,256
+10% +$6.49K ﹤0.01% 5663
2025
Q3 		$63.8K Sell
50,633
-1,870
-4% -$2.96K ﹤0.01% 5601
2025
Q2 		$109K Sell
52,503
-15,220
-22% -$31.1K ﹤0.01% 5252
2025
Q1 		$149K Buy
67,723
+9,625
+17% +$18.7K ﹤0.01% 4943
2024
Q4 		$88.9K Sell
58,098
-7,559
-12% -$12.3K ﹤0.01% 5015
2024
Q3 		$131K Buy
65,657
+325
+0.5% +$776 ﹤0.01% 4834
2024
Q2 		$229K Buy
65,332
+13,941
+27% +$42.8K ﹤0.01% 4462
2024
Q1 		$142K Buy
51,391
+23,038
+81% +$57.9K ﹤0.01% 4590
2023
Q4 		$48.2K Sell
28,353
-4,342
-13% -$4.78K ﹤0.01% 4654
2023
Q3 		$33.7K Sell
32,695
-830
-2% -$1.18K ﹤0.01% 4562
2023
Q2 		$38.9K Buy
33,525
+20,575
+159% +$36.7K ﹤0.01% 4453
2023
Q1 		$19.6K Buy
12,950
+1,000
+8% +$2.5K ﹤0.01% 4412
2022
Q4 		$29.9K Sell
11,950
-2,000
-14% -$6.44K ﹤0.01% 4330
2022
Q3 		$59K Sell
13,950
-1,100
-7% -$4.3K ﹤0.01% 4211
2022
Q2 		$42K Sell
15,050
-1,450
-9% -$5.82K ﹤0.01% 4257
2022
Q1 		$94K Buy
16,500
+250
+2% +$1.83K ﹤0.01% 3988
2021
Q4 		$148K Buy
16,250
+1,307
+9% +$13.3K ﹤0.01% 4059
2021
Q3 		$160K Sell
14,943
-5,522
-27% -$67.2K ﹤0.01% 4048
2021
Q2 		$318K Buy
20,465
+5,265
+35% +$83.8K ﹤0.01% 3547
2021
Q1 		$246K Buy
15,200
+2,990
+24% +$53.3K ﹤0.01% 3614
2020
Q4 		$258K Sell
12,210
-9,573
-44% -$166K ﹤0.01% 3330
2020
Q3 		$323K Buy
21,783
+3,125
+17% +$48.8K ﹤0.01% 2853
2020
Q2 		$274K Buy
+18,658
New +$307K ﹤0.01% 2903
2018
Q3 		– Sell
-6,144
Closed -$239K – 3261
2018
Q2 		$239K Buy
+6,144
New +$196K ﹤0.01% 2855

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

LPL Financial's HRTX Position: Q1 2026 in Review

LPL Financial increased its Heron Therapeutics (HRTX) stake by 41% in Q1 2026, buying an estimated $26.4K and bringing the position to 78,684 shares worth $63K. The position accounts for ﹤0.01% of the portfolio, ranked #5750.

LPL Financial first reported a position in HRTX in Q2 2018 and has held it in 25 quarters since. The position peaked at $323K in Q3 2020. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • LPL Financial held 78,684 shares of Heron Therapeutics worth $63K as of Q1 2026.
  • LPL Financial bought 22,795 Heron Therapeutics shares in Q1 2026, an estimated $26.4K.
  • Heron Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #5750 holding.
  • LPL Financial first reported a position in Heron Therapeutics in Q2 2018 and has held it in 25 quarters since.
  • LPL Financial's Heron Therapeutics position peaked at $323K in Q3 2020.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.